Market Place
Sourcing Support
Enforcement Report - Week of June 7, 2023
07 Jun 2023 //
FDA
AcelRx Pharmaceuticals Announces Divestment of DSUVIA® to Alora Pharmaceuticals
14 Mar 2023 //
PR NEWSWIRE
AcelRx Pharmaceuticals Announces Peer-Reviewed Publication On the Use of DSUVIA
01 Mar 2023 //
PR NEWSWIRE
AcelRx Pharma Announces Abstract Acceptance at the ANESTHESIOLOGY 2022
10 Aug 2022 //
PR NEWSWIRE
AcelRx to Publish Results from Investigator-Initiated Trial on SST
10 May 2022 //
PRNEWSWIRE
Minimal Side Effects and Short Recovery Time Reported for DSUVIA®
25 Apr 2022 //
PRNEWSWIRE
AcelRx to publish Opioid-Sparing Surgery Showing Potential of Sufentanil
12 Jan 2022 //
PRNEWSWIRE
Presentation on the Effect of the Administration of Sufentanil Sublingual Tablet
26 Aug 2021 //
PRNEWSWIRE
FDA rebukes AcelRx for promo for potent opioid drug Dsuvia
19 Feb 2021 //
FIERCE PHARMA
AcelRx Awarded U.S. Army Contract for DSUVIA®
22 Sep 2020 //
PRNEWSWIRE
AcelRx Pharmaceuticals to Present at the Jefferies Virtual Healthcare Conference
02 Jun 2020 //
PRNEWSWIRE
AcelRx Says Grünenthal Said It Is Exercising RightTo Terminate License Agreement
22 May 2020 //
REUTERS
Enforcement Report - Week of January 22, 2020
22 Jan 2020 //
FDA
Enforcement Report - Week of December 18, 2019
18 Dec 2019 //
FDA
AcelRx announces the closing of a $25 million senior secured debt facility
04 Jun 2019 //
PR NEWSWIRE
Public Citizen, FDA Advisor Call for Moratorium on Opioid Approvals
22 Mar 2019 //
RAPS
AcelRx Pharma`s sufentanil SL tablet to be presented at Boswick B&W Symposium
31 Jan 2019 //
PR NEWSWIRE
FDA opioid adcomm chair blasts ‘willful blindness that borders on the criminal’
24 Jan 2019 //
ENDPTS
New FDA approved synthetic opioid serves a good purpose
13 Nov 2018 //
THE HILL
FDA chief defends green light for AcelRx’s controversial opioid
06 Nov 2018 //
FIERCE PHARMA
Trevena hammered again as the FDA spurns their controversial pain drug
03 Nov 2018 //
ENDPTS
FDA approves AcelRx Pharma`s opioid pain drug
03 Nov 2018 //
REUTERS
FDA Commissioner statement on approval of Dsuvia
03 Nov 2018 //
FDA
Dsuvia: Everything you need to know about the new opioid painkiller
01 Nov 2018 //
ABCNEWS
FDA may Approve A New Opioid, Scientists Are Alarmed
19 Oct 2018 //
BUZZFEED
1 year after FDA snub, Adv-comm recommends AcelRx`s Dsuvia for approval
15 Oct 2018 //
FIERCE BIOTECH
Experts offer solid endorsement for AcelRx pain med, spurring a big rally
15 Oct 2018 //
ENDPTS
FDA advisory panel approves AcelRx`s opioid pain drug Dsuvia
15 Oct 2018 //
PHARMA FILE
With Opioid Abuse in Mind, FDA Adv-Comm Recommends AcelRx`s Opioid Dsuvia
15 Oct 2018 //
BIOSPACE
AcelRx shares surge after FDA staff says opioid safe
11 Oct 2018 //
REUTERS
EU approval for AcelRx` Dzuveo
28 Jun 2018 //
PHARMA TIMES
AcelRx resubmits New Drug Application for DSUVIA™
09 May 2018 //
PR NEWSWIRE
Enforcement Report - Week of February 14, 2018
14 Feb 2018 //
FDA
AcelRx Pharmaceuticals Appoints Vincent J. Angotti Chief Executive Officer
16 Feb 2017 //
PR NEWSWIRE
US FDA Enforcement report - 16/Mar/2016
16 Mar 2016 //
FDA
AcelRx Presents Ph3 Results from ARX-04 Clinical Program
11 Feb 2016 //
PR NEWSWIRE
AcelRx announces USFDA conditionally accepts Dsuvia as brand name for ARX-04
10 Jan 2016 //
PHARMABIZ
AcelRx Complete Protocol with FDA,Plans Initiate Ph3 OpenLabel Study for Zalviso
06 Jan 2016 //
PR NEWS WIRE
AcelRx Pharmaceuticals` Zalviso approved in EU for Post operative pain
02 Oct 2015 //
EMA
PDL BioPharma Acquires a Portion of AcelRx Pharmaceuticals`
21 Sep 2015 //
PR NEWS WIRE
Stymied at FDA, AcelRx claims success with PhIII pain study
09 Sep 2015 //
FIERCE BIOTECH
Acelrx Hammered (Again) After FDA Demands A New Zalviso Study After All
09 Mar 2015 //
FIERCE BIOTEC
